License-Out
Helping companies with innovative drugs, medical devices, biotechnology, or other healthcare innovation assets find suitable domestic and international partners to promote asset licensing and commercial cooperation.
T-Capital connects healthcare innovation assets, industrial resources, and domestic and international partners, providing advisory services for licensing, BD, co-development, commercial partnerships, and cross-border transactions.
The value of healthcare innovation assets often depends on who develops and commercializes them, and what kind of resource synergy the partners can create.
For asset holders, the core of License & BD is not just finding a willing partner, but a partner who truly understands the value of the asset, has the corresponding capabilities, and is willing to invest the necessary resources.
For companies looking to bring in external innovation assets, BD is not just about project sourcing, but about finding assets with strategic value that align with their own product pipeline, R&D capabilities, commercialization strategy, and market layout.
T-Capital participates from both a transactional and an industrial perspective, helping companies connect innovative assets with the right partnerships.
T-Capital helps design the appropriate cooperation path based on the company\'s asset type, development stage, commercialization goals, and strategic needs.
Helping companies with innovative drugs, medical devices, biotechnology, or other healthcare innovation assets find suitable domestic and international partners to promote asset licensing and commercial cooperation.
Finding external innovative assets with potential value based on a company's product pipeline, R&D capabilities, and commercialization strategy, and assisting in project screening, business communication, and transactions.
Exploring co-development, joint investment, and other long-term cooperation models for projects that require shared investment in R&D, clinical trials, registration, or commercialization.
Helping companies find partners that can create real industrial synergy based on their commercialization capabilities, channel resources, market coverage, and regional layout.
There is no single standard transaction model for License & BD. The scope of cooperation, arrangement of rights, mutual investment, and business objectives will all affect the final structure.
Establishing licensing partnerships around technology, products, patents, drug candidates, or other innovative assets.
Both parties jointly undertake R&D or development work, with cooperation mechanisms designed based on the project stage and resource investment.
Jointly promoting the market value of a product by combining the commercialization capabilities, market channels, and regional resources of both parties.
Combining technology, capital, R&D, industrial, and commercial resources through long-term strategic cooperation.
Conducting licensing, transfer, and other forms of asset transactions for specific innovative assets or products.
Connecting Chinese and overseas companies, R&D institutions, and industrial capital to support cross-border asset cooperation and transactions.
T-Capital participates in the key nodes of the BD process, helping companies move progressively from project positioning and partner screening to transaction execution.
Understand the company's products, technology, intellectual property, R&D stage, commercialization status, and cooperation goals to clarify the problems to be solved.
Determine suitable partners, transaction models, and cooperation scope based on asset value, market environment, and corporate strategy.
Screening for potential partners with strategic fit based on our healthcare industry network and capital market resources.
Assisting in project introductions, business communications, discussions of intent, transaction structuring, and negotiation of key commercial terms.
Supporting key aspects such as due diligence, contract discussions, implementation of transaction conditions, and project closing.
A promising innovation project does not mean that any potential partner is suitable. Whether a partner has the corresponding R&D, registration, production, commercialization, or global market capabilities often directly affects the future value realization of the asset.
Different healthcare assets have different development cycles, regulatory requirements, and commercialization logic. T-Capital conducts analysis and partner matching based on the specific circumstances of each project.
Innovative drugs, drug candidates, clinical-stage projects, and related R&D platforms.
Biotechnology, innovative technology platforms, and R&D assets with industrialization potential.
Innovative medical devices, high-value consumables, equipment, and related technology products.
IVD, molecular diagnostics, testing technologies, and other assets related to medical diagnostics.
AI in healthcare, digital health, and other healthcare technologies and products.
Other healthcare innovation assets with technological, product, or commercial value.
Cooperation on healthcare innovation assets is increasingly international. Chinese companies may need to find overseas technologies and products, while overseas innovative companies may need to find Chinese partners and commercialization resources.
For projects with cross-border needs, T-Capital can assist in finding potential domestic and international partners based on the specific assets, target markets, and cooperation goals, and facilitate project communication and transaction arrangements.
Learn About Cross-Border Services →The value of License & BD is ultimately validated through real transactions and industrial cooperation. Learn about the healthcare transaction cases T-Capital has been involved in.
View T-Capital Transactions →If your project involves specific products, technologies, or cross-border cooperation, you can discuss the project situation directly with the T-Capital team.
Submit Project Inquiry →License & BD is a service that involves finding partners and promoting business cooperation for healthcare technologies, products, intellectual property, or innovative assets. Forms of cooperation can include license-out, license-in, co-development, commercial partnerships, strategic partnerships, and cross-border asset transactions.
Yes. For companies wishing to license out their technology, products, or innovative assets, T-Capital can screen potential partners based on the project's characteristics, the company's strategy, and the target market. We also assist with project introductions, business communications, transaction structuring, and negotiations.
License-out typically involves an asset owner finding an external partner to license its product, technology, or related rights. License-in, on the other hand, usually involves a company actively seeking external innovative assets to bring in products or technologies that fit its own strategy. The transaction logic and partner screening criteria for the two are different.
No. Licensing transactions can involve innovative drugs, biotechnology, medical devices, diagnostic technologies, digital health, and other healthcare assets with clear intellectual property or commercial value. The specific cooperation model depends on the asset type, development stage, regional rights, and the strategic needs of both parties.
For projects with international needs, T-Capital can assist in finding domestic and overseas partners based on the specific situation and support business communication and transaction advancement for cross-border projects. Cross-border transactions require specific analysis based on the target market, the scope of asset rights, the transaction structure, and relevant regulatory requirements.
Whether it\'s license-out, license-in, co-development, or cross-border BD, tell us the basic situation and cooperation goals of your project, and we can discuss possible transaction paths together.
Contact Us →